Table 1.
Summary of clinical parameters in measured patients: histology types and grades of tumours and receptor positivity
| pCR | Non-pCR | Total number | |
|---|---|---|---|
| Number of lesions | 7 (17 %) | 35 (83 %) | 42 |
| Age, yearsa | 55 ± 11 | 52 ± 10 | 52 ± 10 |
| Tumour histology | |||
| IDC | 7 | 34 | 41 |
| ILC | 0 | 1 | 1 |
| Histological grade | |||
| 1 | 0 | 1 | 1 |
| 2 | 0 | 11 | 11 |
| 3 | 7 | 23 | 30 |
| Oestrogen receptor | |||
| Positive | 3 (43 %) | 24 (69 %) | 27 (64 %) |
| Negative | 4 (57 %) | 11 (31 %) | 15 (36 %) |
| Progesterone receptor | |||
| Positive | 0 (0 %) | 13 (37 %) | 13 (31 %) |
| Negative | 7 (100 %) | 22 (63 %) | 29 (69 %) |
| HER-2/neu | |||
| Positive | 1 (14 %) | 4 (11 %) | 5 (12 %) |
| Negative | 6 (86 %) | 31 (89 %) | 37 (88 %) |
| Oestrogen & Progesterone | |||
| Positive | 1 (14 %) | 13 (37 %) | 14 (33 %) |
| Triple-negative | 3 (43 %) | 9 (26 %) | 12 (29 %) |
| Tumour diameter | Mean | ||
| Pre-treatmenta (BS) | 4.7 ± 2.3 | 5.7 ± 3.0 | 5.6 ± 3.0 |
Note: pCR pathologic complete response, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma. Percentages are from the number of patients in the specific pCR/non-pCR/total group
aMean ± standard deviation